Novel risk factors for venous thromboembolism

Hematology/Oncology Clinics of North America

Volumn 24, Issue 4, 2010, Pages 709-716

  Squizzato, Alessandro ^a   Brivio, Lorenza ^a   Appio, Lorena ^a   Dentali, Francesco ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Cushing syndrome; Hyperthyroidism; JAK2 mutation; Metabolic syndrome; Risk factors; Venous thromboembolism

Indexed keywords

JANUS KINASE 2;

CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DYSLIPIDEMIA; GENE MUTATION; HUMAN; HYPERCORTISOLISM; HYPERTENSION; HYPERTHYROIDISM; LUNG EMBOLISM; OBESITY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; THROMBOPHILIA; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; ENDOCRINE SYSTEM DISEASES; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 77955103318     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.05.007     Document Type: Review

References (50)

1. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 1999, 353:1167-1173.
2. Kyrle P.A., Eichinger S. Deep vein thrombosis. Lancet 2005, 365(9465):1163-1174.
3. Tapson V.F. Acute pulmonary embolism. N Engl J Med 2008, 358(10):1037-1052.
4. Prandoni P. Links between arterial and venous disease. J Intern Med 2007, 262:341-350.
5. Jeries-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease?. Eur Heart J 2005, 26:3-4.
6. Agnelli G., Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases?. J Thromb Haemost 2006, 4:1886-1890.
7. Lowe G.D. Arterial disease and venous thrombosis: are they related, and if so, what should we do about it?. J Thromb Haemost 2006, 4:1882-1885.
8. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link?. J Thromb Haemost 2007, 5(Suppl 1):270-275.
9. Hansson P.O., Eriksson H., Welin L., et al. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: " the Study of Men Born in 1913" Arch Intern Med 1999, 159:1886-1890.
10. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000, 160:3415-3420.
11. Goldhaber S.Z., Grodstein F., Stampfer M.J., et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997, 277:642-645.
12. Stein P.D., Beemath A., Olson R.E. Obesity as a risk factor in venous thromboembolism. Am J Med 2005, 118:978-980.
13. Vaya A., Mira Y., Ferrando F., et al. Hyperlipidemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol 2002, 118:255-259.
14. Deguchi H., Pecheniuk N.M., Elias D.J., et al. High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation 2005, 112:893-899.
15. Doggen C.J., Smith N.L., Lemaitre R.N., et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004, 24:1970-1975.
16. Marcucci R., Liotta A.A., Cellai A.P., et al. Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 2003, 115:601-605.
17. Petrauskiene V., Falk M., Waernbaum I., et al. The risk of venous thromboembolism is markedly elevated in patients with diabetes. Diabetologia 2005, 48:1017-1021.
18. Tsai A.W., Cushman M., Rosamond W.D., et al. Cardiovascular risk factors and venous thromboembolism incidence. Arch Intern Med 2002, 162:1182-1189.
19. Glynn R.J., Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005, 162:975-982.
20. Ageno W., Becattini C., Brighton T., et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008, 117:93-102.
21. Ageno W., Prandoni P., Romualdi E., et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006, 4:1914-1918.
22. Ay C., Tengler T., Vormittag R., et al. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica 2007, 92:374-380.
23. Jang M.J., Choi W.I., Bang S.M., et al. Metabolic syndrome is associated with venous thromboembolism in the Korean population. Arterioscler Thromb Vasc Biol 2009, 29(3):311-315.
24. Squizzato A., Galli M., Romualdi E., et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. Eur Heart J 2010, 31(10):1248-1256.
25. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med 1995, 123:656-664.
26. Valla D., Casadevall N., Huisse M.G., et al. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988, 94:1063-1069.
27. Chait Y., Condat B., Cazals-Hatem D., et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005, 129:553-560.
28. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
29. Dentali F., Squizzato A., Brivio L., et al. JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009, 113(22):5617-5623.
30. Lussana F., Caberlon S., Pagani C., et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009, 124(4):409-417.
31. Hexner E.O. JAK2 V617F: implications for thrombosis in myeloproliferative diseases. Curr Opin Hematol 2007, 14:450-454.
32. Austin S.K., Lambert J.R. The JAK2(V617F) mutation and thrombosis. Br J Haematol 2008, 143:307-320.
33. Squizzato A., Gerdes V.E., Ageno W., et al. The coagulation system in endocrine disorders: a narrative review. Intern Emerg Med 2007, 2:76-83.
34. Squizzato A., Romualdi E., Büller H.R., et al. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. Clin Endocrinol Metab 2007, 92(7):2415-2420.
35. Van Zaane B., Nur E., Squizzato A., et al. Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 2009, 94:2743-2750.
36. Targher G., Pichiri I., Zoppini G., et al. Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review. Semin Thromb Hemost 2009, 35:605-612.
37. van Zaane B., Reuwer A.Q., Büller H.R., et al. Hormones and cardiovascular disease: a shift in paradigm with clinical consequences?. Semin Thromb Hemost 2009, 35:478-487.
38. Squizzato A., Gerdes V.E.A., Brandjes D.P.M., et al. Thyroid diseases and cerebrovascular disease. Stroke 2005, 36:2302-2310.
39. Hofbauer L.C., Heufelder A.E. Coagulation disorders in thyroid diseases. Eur J Endocrinol 1997, 136:1-7.
40. Shih C.H., Chen S.L., Yen C.C., et al. Thyroid hormone receptor dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology 2004, 145:2804-2814.
41. Rogers J.S., Stanley R.S. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983, 102:444-449.
42. Graninger W., Pirich K.R., Speiser W. Effect of thyroid hormones on plasma protein concentrations in man. J Clin Endocrinol Metab 1986, 63:407-411.
43. Squizzato A., Romualdi E., Piantanida E., et al. Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thromb Haemost 2007, 97(5):803-806.
44. Newell-Price J., Bertagna X., Grossman A.B., et al. Cushing's syndrome. Lancet 2006, 367(9522):1605-1617.
45. Erem C., Nuhoglu I., Yilmaz M., et al. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 2009, 32:169-174.
46. Kastelan D., Dusek T., Kraljevic I., et al. Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 2009, 36:70-74.
47. Dekkers O.M., Biermasz N.R., Pereira A.M., et al. Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 2007, 92:976-981.
48. Etxabe J., Vazquez J.A. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479-484.
49. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl 6):381S-453S.
50. Lippi G., Franchini M., Favaloro E.J. Unsuspected triggers of venous thromboembolism-trivial or not so trivial?. Semin Thromb Hemost 2009, 35(7):597-604.